Demographic data, comorbidities, quality of life, and survival probability of biologic therapy associated with sex-specific differences in psoriasis in the Czech Republic

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00669806%3A_____%2F21%3A10422538" target="_blank" >RIV/00669806:_____/21:10422538 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11120/21:43921105 RIV/00216208:11140/21:10422538 RIV/00216208:11110/21:10422538 RIV/00098892:_____/21:N0000095 a 3 dalších

Výsledek na webu

<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=ai.Jxrgyyd" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=ai.Jxrgyyd</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1111/dth.14849" target="_blank" >10.1111/dth.14849</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Demographic data, comorbidities, quality of life, and survival probability of biologic therapy associated with sex-specific differences in psoriasis in the Czech Republic

Popis výsledku v původním jazyce

BIOREP is a Czech registry of patients with psoriasis undergoing biological treatment. The objective of the study was to compare differences in demographic data, previous therapy, comorbidities, severity of psoriasis, quality of life, drug survival rates, and reasons for discontinuation between men and women. We analyzed a cohort of patients from the registry treated between May 2005 and January 2020. The total study population of 2,472 patients (4,051 treatment series) included 913 females and 1,559 males. Women were significantly older than men at the onset of the biological treatment (47.8 vs. 45.4 years, p &lt; 0.0012) and the mean durations of psoriasis and that from its diagnosis until initiation of biological therapy, were longer in women (29.6 vs. 27.2 years and 23.2 vs. 20.6 years, p &lt; 0.0012). Women as compared with men were also more often diagnosed with psoriatic arthritis (43.5% vs. 33.0%, p &lt; 0.0012). The prevalence rate of comorbidities was equivalent for both sexes except for that of depression (11.4% females vs. 3.7% males, p &lt; 0.0012). Both the DLQI and PASI scores were significantly different at baseline (DLQI = 16.0 and PASI = 19.5 for men vs. DLQI 17.6 = and PASI = 17.7 for women, p &lt; 0.0012). The survival probability with biological therapy was significantly lower in women for both biologically naïve and non-naïve patients, and there was more evidence of adverse effects in women. Our research demonstrates significant differences relative to multiple factors associated with psoriasis between men and women.

Název v anglickém jazyce

Demographic data, comorbidities, quality of life, and survival probability of biologic therapy associated with sex-specific differences in psoriasis in the Czech Republic

Popis výsledku anglicky

BIOREP is a Czech registry of patients with psoriasis undergoing biological treatment. The objective of the study was to compare differences in demographic data, previous therapy, comorbidities, severity of psoriasis, quality of life, drug survival rates, and reasons for discontinuation between men and women. We analyzed a cohort of patients from the registry treated between May 2005 and January 2020. The total study population of 2,472 patients (4,051 treatment series) included 913 females and 1,559 males. Women were significantly older than men at the onset of the biological treatment (47.8 vs. 45.4 years, p &lt; 0.0012) and the mean durations of psoriasis and that from its diagnosis until initiation of biological therapy, were longer in women (29.6 vs. 27.2 years and 23.2 vs. 20.6 years, p &lt; 0.0012). Women as compared with men were also more often diagnosed with psoriatic arthritis (43.5% vs. 33.0%, p &lt; 0.0012). The prevalence rate of comorbidities was equivalent for both sexes except for that of depression (11.4% females vs. 3.7% males, p &lt; 0.0012). Both the DLQI and PASI scores were significantly different at baseline (DLQI = 16.0 and PASI = 19.5 for men vs. DLQI 17.6 = and PASI = 17.7 for women, p &lt; 0.0012). The survival probability with biological therapy was significantly lower in women for both biologically naïve and non-naïve patients, and there was more evidence of adverse effects in women. Our research demonstrates significant differences relative to multiple factors associated with psoriasis between men and women.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30216 - Dermatology and venereal diseases

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2021

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Dermatologic Therapy

ISSN

1396-0296

e-ISSN

—

Svazek periodika

34

Číslo periodika v rámci svazku

2

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

10

Strana od-do

e14849

Kód UT WoS článku

000617942300001

EID výsledku v databázi Scopus

2-s2.0-85101484558